Lipoxygenase inhibitors for the treatment of pancreatic cancer

Timothy J. Kennedy, Chung Yip Chan, Xian Zhong Ding, Thomas E. Adrian

Research output: Contribution to journalReview articlepeer-review

22 Citations (Scopus)


Pancreatic cancer has a dismal prognosis with no effective medical therapy. Therefore, there is a need to search for novel targets for cancer prevention and treatment. The lipoxygenases oxygenate arachidonic acid and other 20-carbon fatty acids and their downstream metabolites have been found to mediate several aspects of pancreatic cancer development and growth. Therapeutic agents have been developed against various targets in the lipoxygenase pathways. Many of these were first developed for their anti-inflammatory properties and were subsequently found to have anticancer effects. Such agents include lipoxygenase and 5-lipoxygenase-activating protein inhibitors, leukotriene receptor antagonists and natural products with inhibitory effects on these pathways. Dual lipoxygenase and cyclooxygenase inhibition represents an exciting area of research and drug development.

Original languageEnglish
Pages (from-to)525-536
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number4
Publication statusPublished - Aug 2003
Externally publishedYes


  • 5-lipoxygenase-activating protein inhibitors
  • Dual LOX/COX inhibitors
  • LOX inhibitors
  • Leukotriene B4
  • Leukotriene receptor antagonists
  • Lipoxygenase
  • Pancreatic
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Lipoxygenase inhibitors for the treatment of pancreatic cancer'. Together they form a unique fingerprint.

Cite this